<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="14009">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 13, 2016</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00345878</url>
  </required_header>
  <id_info>
    <org_study_id>105926</org_study_id>
    <nct_id>NCT00345878</nct_id>
  </id_info>
  <brief_title>Study to Evaluate the Immune Response and Safety of GSK Biologicals' HPV Vaccine in Healthy Women Aged 18-35 Years</brief_title>
  <official_title>Phase IIIb, Double-blind, Randomized, Controlled Study to Evaluate the Immunogenicity &amp; Safety of GSK Biologicals' HPV-16/18 L1 VLP AS04 Vaccine Administered Intramuscularly ( 0, 1, 6 Month Schedule) in Healthy Women From Malaysia.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <oversight_info>
    <authority>Malaysia: Ministry of Health</authority>
  </oversight_info>
  <brief_summary>
    <textblock>
      Human papillomavirus infection has clearly been recognized as the cause of cervical cancer.
      The infection of the cervix by certain oncogenic types of HPV, if not cleared, can lead to
      cervical cancer in women. This study will evaluate the immunogenicity and safety of the
      HPV-16/18 L1 VLP AS04 vaccine.

      The Protocol Posting has been updated in order to comply with the FDA Amendment Act, Sep
      2007.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The protocol was primarily amended for the following reasons:

        -  Merck's tetravalent HPV vaccine, Gardasil®, has been licensed and is now becoming
           commercially available in an increasing number of countries. Therefore, the study
           procedures were revised to include questions at every visit to determine if subjects
           have received an HPV vaccine outside of the study.

        -  It was decided to offer GSK Biologicals' HPV vaccine to all subjects in the control
           group at the end of the study. The HPV vaccine will be offered to these subjects based
           on its local indication once the vaccine is marketed in Malaysia.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2006</start_date>
  <completion_date type="Actual">December 2007</completion_date>
  <primary_completion_date type="Actual">December 2007</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention</study_design>
  <primary_outcome>
    <measure>Number of Subjects Who Seroconverted for Anti-human Papilloma Virus 16 (Anti-HPV-16) and Anti-human Papilloma Virus 18 (Anti-HPV-18) Antibodies</measure>
    <time_frame>At Month 7</time_frame>
    <safety_issue>No</safety_issue>
    <description>Seroconversion is defined as the appearance of antibodies with titers greater than or equal to the predefined cut-off value in the serum of subjects seronegative before vaccination. Cut-off values assessed include 8 enzyme-linked immunosorbent assay units per milliliter (EL.U/mL) for anti-HPV-16 antibodies and 7 EL.U/mL for anti-HPV-18 antibodies.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Titers of Anti-human Papilloma Virus 16 (Anti-HPV-16) and Anti-human Papilloma Virus 18 (Anti-HPV-18) Antibodies</measure>
    <time_frame>At Month 0 and Month 7</time_frame>
    <safety_issue>No</safety_issue>
    <description>Titers are given as Geometric Mean Titers (GMTs) expressed as Enzyme-linked Immunosorbent Assay Units Per Milliliter (EL.U/mL).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects Reporting Solicited Symptoms</measure>
    <time_frame>During the 7 days after each vaccination</time_frame>
    <safety_issue>No</safety_issue>
    <description>Solicited local symptoms assessed include pain, redness and swelling. Solicited general symptoms assessed include arthralgia, fatigue, fever, gastro-intestinal symptoms, headache, myalgia, rash and urticaria.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects Reporting Unsolicited Adverse Events (AEs)</measure>
    <time_frame>Within 30 days after any vaccination</time_frame>
    <safety_issue>No</safety_issue>
    <description>Unsolicited adverse event = Any adverse event (AE) reported in addition to those solicited during the clinical study. Also any &quot;solicited&quot; symptom with onset outside the specified period of follow-up for solicited symptoms was reported as an unsolicited adverse event.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects Reporting Unsolicited Adverse Events as New Onset Chronic Diseases (NOCDs) and Other Medically Significant Adverse Events (AEs)</measure>
    <time_frame>Throughout the study period (up to Month 7)</time_frame>
    <safety_issue>No</safety_issue>
    <description>NOCDs assessed include e.g. autoimmune disorders, asthma, type I diabetes, allergies,...
Medically significant AEs assessed include AEs prompting emergency room or physician visits that are not related to common diseases or routine visits for physical examination or vaccination, or SAEs that are not related to common diseases.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects Reporting Serious Adverse Events</measure>
    <time_frame>Throughout the study period (up to Month 7)</time_frame>
    <safety_issue>No</safety_issue>
    <description>Serious adverse events assessed include medical occurrences that results in death, is life threatening, require hospitalization or prolongation of hospitalization, result in disability/incapacity or are a congenital anomaly/birth defect in the offspring of a study subject.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">271</enrollment>
  <condition>Human Papillomavirus (HPV) Infection</condition>
  <condition>Associated Cervical Neoplasia</condition>
  <condition>Papillomavirus Vaccines</condition>
  <arm_group>
    <arm_group_label>Cervarix Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects received 3 doses of HPV-16/18 L1 VLP AS04 (Cervarix™) according to a 0, 1, 6-month schedule.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo Group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Subjects received 3 doses of Placebo according to a 0, 1, 6-month schedule.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Three doses of vaccine administered intramuscularly according to a 0, 1, 6-month schedule.</description>
    <arm_group_label>Placebo Group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>HPV-16/18 L1 VLP AS04 (Cervarix TM)</intervention_name>
    <description>Three doses of vaccine administered intramuscularly according to a 0, 1, 6-month schedule.</description>
    <arm_group_label>Cervarix Group</arm_group_label>
    <other_name>GSK Biologicals' HPV-16/18 VLP/AS04 vaccine</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects who the investigator believes that they can and will comply with the
             requirements of the protocol should be enrolled in the study.

          -  A female from Malaysia between, and including, 18 and 35 years of age at the time of
             the first vaccination.

          -  Written informed consent obtained from the subject.

          -  Healthy subjects as established by medical history and clinical examination before
             entering into the study.

          -  Subjects must have a negative urine pregnancy test.

          -  Subjects of childbearing potential at the time of study entry must be abstinent or
             must be using an effective method of birth control for 30 days prior to vaccination
             and must agree to continue such precautions for two months after completion of the
             vaccination series.

        Exclusion Criteria:

          -  Use of any investigational or non-registered product (drug or vaccine) other than the
             study vaccine(s) within 30 days preceding the first dose of study vaccine, or planned
             use during the study period.

          -  Chronic administration (defined as more than 14 days) of immunosuppressants or other
             immune-modifying drugs within six months prior to the first vaccine dose.

          -  Planned administration/administration of a vaccine not foreseen by the study protocol
             within 30 days before and 30 days after the first dose of vaccine. Administration of
             routine vaccines up to 8 days before the first dose of study vaccine is allowed.
             Enrolment will be deferred until the subject is outside of specified window.

          -  previous administration of components of the investigational vaccine

          -  Previous vaccination against HPV or planned administration of any HPV vaccine other
             than that foreseen by the study protocol during the study period.

          -  Any confirmed or suspected immunosuppressive or immunodeficient condition, based on
             medical history and physical examination.

          -  History of allergic disease or reactions likely to be exacerbated by any component of
             the vaccine(s).

          -  Hypersensitivity to latex.

          -  Acute disease at the time of enrolment.

          -  Known acute or chronic, clinically significant neurologic, pulmonary, cardiovascular,
             hepatic or renal functional abnormality, as determined by previous physical
             examination or laboratory tests.

          -  History of chronic condition(s) requiring treatment.

          -  Administration of immunoglobulins and/or any blood product within three months
             preceding the first dose of study vaccine(s) or planned administration during the
             study period. Enrolment will be deferred until the subject is outside of specified
             window.

          -  Pregnant or lactating female.

          -  Female planning to become pregnant or planning to discontinue contraceptive
             precautions.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>35 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Kerajaan Persekutuan Putrajaya</city>
        <zip>62250</zip>
        <country>Malaysia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Kuala Lumpur</city>
        <zip>50603</zip>
        <country>Malaysia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Malaysia</country>
  </location_countries>
  <reference>
    <citation>Verstraeten T, Descamps D, David MP, Zahaf T, Hardt K, Izurieta P, Dubin G, Breuer T. Analysis of adverse events of potential autoimmune aetiology in a large integrated safety database of AS04 adjuvanted vaccines. Vaccine. 2008 Dec 2;26(51):6630-8. doi: 10.1016/j.vaccine.2008.09.049.</citation>
    <PMID>18845199</PMID>
  </reference>
  <verification_date>March 2011</verification_date>
  <lastchanged_date>March 17, 2011</lastchanged_date>
  <firstreceived_date>June 28, 2006</firstreceived_date>
  <firstreceived_results_date>November 12, 2009</firstreceived_results_date>
  <responsible_party>
    <name_title>Cheri Hudson; Clinical Disclosure Advisor</name_title>
    <organization>GSK Clinical Disclosure</organization>
  </responsible_party>
  <keyword>HPV-16/18 L1 VLP AS04</keyword>
  <keyword>Cervical neoplasia</keyword>
  <keyword>Cervical cancer</keyword>
  <keyword>Human Papillomavirus (HPV)</keyword>
  <keyword>Double-blind</keyword>
  <keyword>AS04</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Cervarix Group</title>
          <description>Subjects received 3 doses of HPV-16/18 L1 VLP AS04 (Cervarix™) according to a 0, 1, 6-month schedule.</description>
        </group>
        <group group_id="P2">
          <title>Placebo Group</title>
          <description>Subjects received 3 doses of Placebo according to a 0, 1, 6-month schedule.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="135"/>
                <participants group_id="P2" count="136"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="131"/>
                <participants group_id="P2" count="135"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Unknown</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Cervarix Group</title>
          <description>Subjects received 3 doses of HPV-16/18 L1 VLP AS04 (Cervarix™) according to a 0, 1, 6-month schedule.</description>
        </group>
        <group group_id="B2">
          <title>Placebo Group</title>
          <description>Subjects received 3 doses of Placebo according to a 0, 1, 6-month schedule.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <measure_list>
        <measure>
          <title>Number of Participants</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="135"/>
                <measurement group_id="B2" value="136"/>
                <measurement group_id="B3" value="271"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="24.8" spread="3.91"/>
                <measurement group_id="B2" value="25.0" spread="4.14"/>
                <measurement group_id="B3" value="24.9" spread="4.02"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Subjects</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Female</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="135"/>
                <measurement group_id="B2" value="136"/>
                <measurement group_id="B3" value="271"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Male</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
                <measurement group_id="B2" value="0"/>
                <measurement group_id="B3" value="0"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Subjects Who Seroconverted for Anti-human Papilloma Virus 16 (Anti-HPV-16) and Anti-human Papilloma Virus 18 (Anti-HPV-18) Antibodies</title>
        <description>Seroconversion is defined as the appearance of antibodies with titers greater than or equal to the predefined cut-off value in the serum of subjects seronegative before vaccination. Cut-off values assessed include 8 enzyme-linked immunosorbent assay units per milliliter (EL.U/mL) for anti-HPV-16 antibodies and 7 EL.U/mL for anti-HPV-18 antibodies.</description>
        <time_frame>At Month 7</time_frame>
        <safety_issue>No</safety_issue>
        <population>Analysis was performed on the According-to-Protocol (ATP) cohort for analysis of immunogenicity.</population>
        <group_list>
          <group group_id="O1">
            <title>Cervarix Group</title>
            <description>Subjects received 3 doses of HPV-16/18 L1 VLP AS04 (Cervarix™) according to a 0, 1, 6-month schedule.</description>
          </group>
          <group group_id="O2">
            <title>Placebo Group</title>
            <description>Subjects received 3 doses of Placebo according to a 0, 1, 6-month schedule.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="112"/>
                  <measurement group_id="O2" value="115"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of Subjects Who Seroconverted for Anti-human Papilloma Virus 16 (Anti-HPV-16) and Anti-human Papilloma Virus 18 (Anti-HPV-18) Antibodies</title>
            <description>Seroconversion is defined as the appearance of antibodies with titers greater than or equal to the predefined cut-off value in the serum of subjects seronegative before vaccination. Cut-off values assessed include 8 enzyme-linked immunosorbent assay units per milliliter (EL.U/mL) for anti-HPV-16 antibodies and 7 EL.U/mL for anti-HPV-18 antibodies.</description>
            <units>Subjects</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>Anti-HPV16 (n=112, 115)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="112"/>
                  <measurement group_id="O2" value="4"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Anti-HPV18 (n=106, 113)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="106"/>
                  <measurement group_id="O2" value="2"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Titers of Anti-human Papilloma Virus 16 (Anti-HPV-16) and Anti-human Papilloma Virus 18 (Anti-HPV-18) Antibodies</title>
        <description>Titers are given as Geometric Mean Titers (GMTs) expressed as Enzyme-linked Immunosorbent Assay Units Per Milliliter (EL.U/mL).</description>
        <time_frame>At Month 0 and Month 7</time_frame>
        <safety_issue>No</safety_issue>
        <population>Analysis was performed on the According-to-Protocol (ATP) cohort for analysis of immunogenicity.</population>
        <group_list>
          <group group_id="O1">
            <title>Cervarix Group</title>
            <description>Subjects received 3 doses of HPV-16/18 L1 VLP AS04 (Cervarix™) according to a 0, 1, 6-month schedule.</description>
          </group>
          <group group_id="O2">
            <title>Placebo Group</title>
            <description>Subjects received 3 doses of Placebo according to a 0, 1, 6-month schedule.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="126"/>
                  <measurement group_id="O2" value="129"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Titers of Anti-human Papilloma Virus 16 (Anti-HPV-16) and Anti-human Papilloma Virus 18 (Anti-HPV-18) Antibodies</title>
            <description>Titers are given as Geometric Mean Titers (GMTs) expressed as Enzyme-linked Immunosorbent Assay Units Per Milliliter (EL.U/mL).</description>
            <units>EL.U/mL</units>
            <param>Geometric Mean</param>
            <dispersion>95% Confidence Interval</dispersion>
            <category_list>
              <category>
                <sub_title>Anti-HPV16 (at Month 0) (n=126, 129)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="5.1" lower_limit="4.3" upper_limit="6.0"/>
                  <measurement group_id="O2" value="4.6" lower_limit="4.2" upper_limit="5.0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Anti-HPV16 (at Month 7) (n=126, 127)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="11133.3" lower_limit="9817.6" upper_limit="12625.3"/>
                  <measurement group_id="O2" value="4.7" lower_limit="4.2" upper_limit="5.3"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Anti-HPV18 (at Month 0) (n=122, 127)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="4.3" lower_limit="3.9" upper_limit="4.7"/>
                  <measurement group_id="O2" value="4.2" lower_limit="3.8" upper_limit="4.7"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Anti-HPV18 (at Month 7) (n=122, 127)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="4264.2" lower_limit="3771.6" upper_limit="4821.2"/>
                  <measurement group_id="O2" value="4.2" lower_limit="3.8" upper_limit="4.7"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects Reporting Solicited Symptoms</title>
        <description>Solicited local symptoms assessed include pain, redness and swelling. Solicited general symptoms assessed include arthralgia, fatigue, fever, gastro-intestinal symptoms, headache, myalgia, rash and urticaria.</description>
        <time_frame>During the 7 days after each vaccination</time_frame>
        <safety_issue>No</safety_issue>
        <population>The analysis was performed on the Total Vaccinated Cohort, on subjects with available data.</population>
        <group_list>
          <group group_id="O1">
            <title>Cervarix Group</title>
            <description>Subjects received 3 doses of HPV-16/18 L1 VLP AS04 (Cervarix™) according to a 0, 1, 6-month schedule.</description>
          </group>
          <group group_id="O2">
            <title>Placebo Group</title>
            <description>Subjects received 3 doses of Placebo according to a 0, 1, 6-month schedule.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="132"/>
                  <measurement group_id="O2" value="135"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of Subjects Reporting Solicited Symptoms</title>
            <description>Solicited local symptoms assessed include pain, redness and swelling. Solicited general symptoms assessed include arthralgia, fatigue, fever, gastro-intestinal symptoms, headache, myalgia, rash and urticaria.</description>
            <units>Subjects</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>Pain</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="121"/>
                  <measurement group_id="O2" value="101"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Redness</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="48"/>
                  <measurement group_id="O2" value="40"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Swelling</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="42"/>
                  <measurement group_id="O2" value="25"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Arthralgia</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="39"/>
                  <measurement group_id="O2" value="26"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Fatigue</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="52"/>
                  <measurement group_id="O2" value="48"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Fever (above 37.5 degree Celsius)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="19"/>
                  <measurement group_id="O2" value="17"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Gastro-intestinal symptoms</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="18"/>
                  <measurement group_id="O2" value="18"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Headache</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="46"/>
                  <measurement group_id="O2" value="47"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Myalgia</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="48"/>
                  <measurement group_id="O2" value="32"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Rash</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="4"/>
                  <measurement group_id="O2" value="7"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Urticaria</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="4"/>
                  <measurement group_id="O2" value="2"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects Reporting Unsolicited Adverse Events (AEs)</title>
        <description>Unsolicited adverse event = Any adverse event (AE) reported in addition to those solicited during the clinical study. Also any &quot;solicited&quot; symptom with onset outside the specified period of follow-up for solicited symptoms was reported as an unsolicited adverse event.</description>
        <time_frame>Within 30 days after any vaccination</time_frame>
        <safety_issue>No</safety_issue>
        <group_list>
          <group group_id="O1">
            <title>Cervarix Group</title>
            <description>Subjects received 3 doses of HPV-16/18 L1 VLP AS04 (Cervarix™) according to a 0, 1, 6-month schedule.</description>
          </group>
          <group group_id="O2">
            <title>Placebo Group</title>
            <description>Subjects received 3 doses of Placebo according to a 0, 1, 6-month schedule.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="135"/>
                  <measurement group_id="O2" value="136"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of Subjects Reporting Unsolicited Adverse Events (AEs)</title>
            <description>Unsolicited adverse event = Any adverse event (AE) reported in addition to those solicited during the clinical study. Also any &quot;solicited&quot; symptom with onset outside the specified period of follow-up for solicited symptoms was reported as an unsolicited adverse event.</description>
            <units>Subjects</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="30"/>
                  <measurement group_id="O2" value="36"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects Reporting Unsolicited Adverse Events as New Onset Chronic Diseases (NOCDs) and Other Medically Significant Adverse Events (AEs)</title>
        <description>NOCDs assessed include e.g. autoimmune disorders, asthma, type I diabetes, allergies,...
Medically significant AEs assessed include AEs prompting emergency room or physician visits that are not related to common diseases or routine visits for physical examination or vaccination, or SAEs that are not related to common diseases.</description>
        <time_frame>Throughout the study period (up to Month 7)</time_frame>
        <safety_issue>No</safety_issue>
        <group_list>
          <group group_id="O1">
            <title>Cervarix Group</title>
            <description>Subjects received 3 doses of HPV-16/18 L1 VLP AS04 (Cervarix™) according to a 0, 1, 6-month schedule.</description>
          </group>
          <group group_id="O2">
            <title>Placebo Group</title>
            <description>Subjects received 3 doses of Placebo according to a 0, 1, 6-month schedule.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="135"/>
                  <measurement group_id="O2" value="136"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of Subjects Reporting Unsolicited Adverse Events as New Onset Chronic Diseases (NOCDs) and Other Medically Significant Adverse Events (AEs)</title>
            <description>NOCDs assessed include e.g. autoimmune disorders, asthma, type I diabetes, allergies,...
Medically significant AEs assessed include AEs prompting emergency room or physician visits that are not related to common diseases or routine visits for physical examination or vaccination, or SAEs that are not related to common diseases.</description>
            <units>Subjects</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>NOCDs</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Medically significant AEs</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="10"/>
                  <measurement group_id="O2" value="11"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects Reporting Serious Adverse Events</title>
        <description>Serious adverse events assessed include medical occurrences that results in death, is life threatening, require hospitalization or prolongation of hospitalization, result in disability/incapacity or are a congenital anomaly/birth defect in the offspring of a study subject.</description>
        <time_frame>Throughout the study period (up to Month 7)</time_frame>
        <safety_issue>No</safety_issue>
        <group_list>
          <group group_id="O1">
            <title>Cervarix Group</title>
            <description>Subjects received 3 doses of HPV-16/18 L1 VLP AS04 (Cervarix™) according to a 0, 1, 6-month schedule.</description>
          </group>
          <group group_id="O2">
            <title>Placebo Group</title>
            <description>Subjects received 3 doses of Placebo according to a 0, 1, 6-month schedule.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="135"/>
                  <measurement group_id="O2" value="136"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of Subjects Reporting Serious Adverse Events</title>
            <description>Serious adverse events assessed include medical occurrences that results in death, is life threatening, require hospitalization or prolongation of hospitalization, result in disability/incapacity or are a congenital anomaly/birth defect in the offspring of a study subject.</description>
            <units>Subjects</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="3"/>
                  <measurement group_id="O2" value="3"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <desc>Events collected by systematic assessment are reported for subjects with a symptom diary card available.
Events collected by a non-systematic method are reported for the Total Vaccinated cohort.</desc>
      <group_list>
        <group group_id="E1">
          <title>Cervarix Group</title>
          <description>Subjects received 3 doses of HPV-16/18 L1 VLP AS04 (Cervarix™) according to a 0, 1, 6-month schedule.</description>
        </group>
        <group group_id="E2">
          <title>Placebo Group</title>
          <description>Subjects received 3 doses of Placebo according to a 0, 1, 6-month schedule.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="135"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="136"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholelithiasis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="135"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="136"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Dengue fever</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="135"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="136"/>
              </event>
              <event>
                <sub_title>Chronic tonsillitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="135"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="136"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Overdose</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="136"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Intervertebral disc protrusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="136"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Pregnancy, puerperium and perinatal conditions</title>
            <event_list>
              <event>
                <sub_title>Abortion missed</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="135"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="136"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nasal turbinate hypertrophy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="135"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="136"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="121"/>
                <counts group_id="E2" subjects_affected="101"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" subjects_affected="121" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="101" subjects_at_risk="135"/>
              </event>
              <event>
                <sub_title>Redness</sub_title>
                <counts group_id="E1" subjects_affected="48" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="40" subjects_at_risk="135"/>
              </event>
              <event>
                <sub_title>Swelling</sub_title>
                <counts group_id="E1" subjects_affected="42" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="25" subjects_at_risk="135"/>
              </event>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="39" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="26" subjects_at_risk="135"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="52" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="48" subjects_at_risk="135"/>
              </event>
              <event>
                <sub_title>Fever (above 37.5 degree Celsius)</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="135"/>
              </event>
              <event>
                <sub_title>Gastro-intestinal symptoms</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="135"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="46" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="47" subjects_at_risk="135"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="48" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="32" subjects_at_risk="135"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="135"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="135"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="136"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="135"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="136"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>GSK Response Center</name_or_title>
      <organization>GlaxoSmithKline</organization>
      <phone>866-435-7343</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>
